Actelion Ltd. (ATLN)’s successful drug-development record has earned the Swiss company the right to stay independent after figures from a lung-medicine study beat its expectations, Chief Executive Officer Jean-Paul Clozel said.
Results from a late-stage trial of the experimental drug selexipag for pulmonary arterial hypertension were twice as good as Clozel expected, the CEO said in an interview yesterday in Basel, Switzerland. With the approval last year of Opsumit for the same disease, the Allschwil-based company has two potential blockbuster treatments for the first time.
Help employers find you! Check out all the jobs and post your resume.
